Private/public partnership to advance development of personalized MM medicines in USA

27 November 2012

In the USA, the Multiple Myeloma Research Foundation (MMRF) and the Department of Veterans Affairs (VA) have entered into an unprecedented public/private partnership to accelerate the development of personalized medicine for multiple myeloma (MM).

Through a novel Cooperative Research and Development Agreement (CRADA), the VA will collaborate with the MMRF on the CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study to speed the progression to targeted treatment approaches for multiple myeloma.

“This critical partnership with the VA reflects our strong commitment to creating public access to cutting-edge scientific data and engaging the widest scientific community possible in the discovery process”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >